Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial - 02/02/21
, Domenica Lorusso, MD c, d, Florence Joly, MD e, f, Ciro Gallo, ProfMD g, Nicoletta Colombo, ProfMD h, i, Cristiana Sessa, ProfMD j, Aristotelis Bamias, ProfMD k, Vanda Salutari, MD l, Frédèric Selle, MD f, m, Simona Frezzini, MD n, o, Ugo De Giorgi, MD p, Patricia Pautier, MD f, q, Alessandra Bologna, MD r, Michele Orditura, ProfMD s, Coraline Dubot, MD f, t, Angiolo Gadducci, ProfMD u, Serafina Mammoliti, MD v, Isabelle Ray-Coquard, ProfMD f, w, Elena Zafarana, MD x, Enrico Breda, MD y, Laure Favier, MD f, z, Antonio Ardizzoia, MD aa, Saverio Cinieri, ProfMD ab, Rémy Largillier, MD ac, Daniela Sambataro, MD ad, Emmanuel Guardiola, MD ae, Rossella Lauria, MD af, Carmela Pisano, MD a, Francesco Raspagliesi, MD d, Giovanni Scambia, MD l, Gennaro Daniele, MD b, c, Francesco Perrone, MD bon behalf of the
MITO16b/MANGO–OV2/ENGOT–ov17 Investigators†
Summary |
Background |
Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent disease not previously treated with the same drug. We aimed to test the value of continuing bevacizumab beyond progression after first-line treatment with the same drug.
Methods |
In our open-label, randomised, phase 3 trial done at 82 sites in four countries, we enrolled women (aged ≥18 years) who had previously received first-line platinum-based therapy including bevacizumab, and had recurrent (≥6 months since last platinum dose), International Federation of Gynaecology and Obstetrics stage IIIB–IV ovarian cancer with an Eastern Cooperative Oncology Group performance status 0–2. Patients were randomly assigned (1:1) to receive a carboplatin-based doublet intravenously (carboplatin area under the concentration curve [AUC] 5 on day 1 plus paclitaxel 175 mg/m2 on day 1, every 21 days; carboplatin AUC 4 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days; or carboplatin AUC 5 on day 1 plus pegylated liposomal doxorubicin 30 mg/m2 on day 1, every 28 days), or a carboplatin-based doublet plus bevacizumab (10 mg/kg intravenous every 14 days combined with pegylated liposomal doxorubicin–carboplatin, or 15 mg/kg every 21 days combined with gemcitabine–carboplatin or paclitaxel–carboplatin). Evaluable disease according to RECIST 1.1 guidelines was required before randomisation. Randomisation was done through the trial website with a minimisation procedure, stratified by centre, time of recurrence, performance status, and type of second-line chemotherapy. The primary endpoint was investigator-assessed progression-free survival, analysed on an intention-to-treat basis. Safety was assessed in all participants who received at least one dose. This trial is registered with ClinicalTrials.gov, NCT01802749 and EudraCT 2012-004362-17.
Findings |
Between Dec 6, 2013, and Nov 11, 2016, 406 patients were recruited (203 [50%] assigned to the bevacizumab group and 203 [50%] to the standard chemotherapy group). 130 patients (64%) in the bevacizumab group and 131 (65%) in the standard chemotherapy group had progressed after receiving a last dose of platinum more than 12 months before, and 146 patients (72%) in the bevacizumab group and 147 (72%) in the standard chemotherapy group had progressed after completion of first-line bevacizumab maintenance. 161 participants (79%) progressed in the standard chemotherapy group, as did 143 (70%) in the bevacizumab group. Median progression-free survival was 8·8 months (95% CI 8·4–9·3) in the standard chemotherapy group and 11·8 months (10·8–12·9) in the bevacizumab group (hazard ratio 0·51, 95% CI 0·41–0·65; log-rank p<0·0001). Most common grade 3–4 adverse events were hypertension (20 [10%] in the standard chemotherapy group vs 58 (29%) in the bevacizumab group), neutrophil count decrease (81 [41%] vs 80 [40%]), and platelet count decrease (43 [22%] vs 61 [30%]). 68 patients (33%) died in the standard chemotherapy group and 79 (39%) died in the bevacizumab group; two deaths (1%) in the standard chemotherapy group and one death (<1%) in the bevacizumab group were deemed to be treatment-related.
Interpretation |
Continuing bevacizumab beyond progression combined with chemotherapy in patients with platinum-sensitive recurrent ovarian cancer improves progression-free survival compared with standard chemotherapy alone and might be considered in clinical practice.
Funding |
Hoffmann–La Roche and Associazione Italiana per la Ricerca sul Cancro.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 2
P. 267-276 - février 2021 Retour au numéro
Article précédent
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
- François Quénet, Dominique Elias, Lise Roca, Diane Goéré, Laurent Ghouti, Marc Pocard, Olivier Facy, Catherine Arvieux, Gérard Lorimier, Denis Pezet, Frédéric Marchal, Valeria Loi, Pierre Meeus, Beata Juzyna, Hélène de Forges, Jacques Paineau, Olivier Glehen, UNICANCER-GI Group and BIG Renape Group, Pascale MARIANI, Cécile BRIGAND, Jean-Marc BEREDER, Simon MSIKA, Guillaume PORTIER, Patrick RAT
- Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
- Robert D Morgan, Iain A McNeish, Adrian D Cook, Elizabeth C James, Rosemary Lord, Graham Dark, Rosalind M Glasspool, Jonathan Krell, Christine Parkinson, Christopher J Poole, Marcia Hall, Dolores Gallardo-Rincón, Michelle Lockley, Sharadah Essapen, Jeff Summers, Anjana Anand, Abel Zachariah, Sarah Williams, Rachel Jones, Kate Scatchard, Axel Walther, Jae-Weon Kim, Sudha Sundar, Gordon C Jayson, Jonathan A Ledermann, Andrew R Clamp
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?